High-dose methotrexate for gestational trophoblastic disease

Area of Science:

• Oncology
• Gynecology
• Pharmacology

Background:

• Gestational trophoblastic neoplasia (GTN) requires effective treatment protocols.
• Evaluating high-dose methotrexate with folinic acid rescue (MTX/FAR) is crucial for GTN management.
• Risk stratification (WHO and NCI classifications) guides GTN treatment selection.

Purpose of the Study:

• To assess the efficacy and safety of single-agent high-dose methotrexate with folinic acid rescue (MTX/FAR) for low- and intermediate-risk GTN.
• To identify factors predicting treatment failure with MTX/FAR in GTN patients.
• To compare the clinical benefit of high-dose MTX/FAR versus conventional dosing for GTN.

Main Methods:

• Retrospective analysis of 85 patients with low- and intermediate-risk GTN treated with single-agent high-dose MTX/FAR.
• Classification of GTN using WHO and NCI criteria (metastatic and nonmetastatic).
• Evaluation of remission rates, treatment courses, salvage therapies, and predictive factors for failure.

Main Results:

• Eighty-four percent (71/85) of patients achieved remission with MTX/FAR; 16% (14/85) required salvage therapy.
• Predictive factors for MTX/FAR failure included elevated pretreatment beta-hCG, prior GTN history, and shorter time from pregnancy termination to treatment.
• Multivariate analysis confirmed pretreatment beta-hCG and short time from pregnancy termination as independent predictors of failure.
• The regimen was well-tolerated with no significant grade 3/4 hematologic or gastrointestinal toxicity.

Conclusions:

• Single-agent high-dose MTX/FAR is an effective and well-tolerated treatment for low- and intermediate-risk GTN.
• Predictors of treatment failure include high pretreatment beta-hCG and a short interval between pregnancy termination and treatment initiation.
• High-dose MTX/FAR does not appear to offer a clinical advantage over conventional dose methotrexate for low- and intermediate-risk GTN.